NicoDerm 14 mg

Natural health product licensed in Canada

Licence holder

Kenvue Canada Inc.

NPN or DIN-HM

02093138

Status

Active licence

Licence date

19 November 2007

Revision date

26 July 2024

Form

Timbre transdermique

Route of administration

Transdermique

Application type

Non traditionnelle

Composition

Medicinal composition not provided.

Non-medicinal ingredients

Siliconized polyester film, High density polyethylene film, Polyisobutylene, Ethylene-vinyl acetate copolymer

Recommended doses in Canada

Uses authorised in Canada

Text supplied in English because no French text is available.

NICODERM(R) 14 mg Step 2 patch is a medicine that can help you stop smoking by reducing withdrawal symptoms and nicotine cravings. NICODERM(R) is a form of nicotine replacement therapy (NRT) that can help double your chances of quitting successfully. NICODERM(R) provides a lower level of nicotine to your blood than cigarettes, and allows you to gradually do away with your body's need for nicotine. It works as a temporary aid to help you quit smoking by reducing nicotine cravings and nicotine withdrawal symptoms such as irritability, frustration, anxiety, difficulty concentrating and restlessness. Without these powerful urges for the cigarettes you "need", getting rid of the "habit" cigarettes becomes much easier. The good news is that NICODERM(R) contains no tar or carbon monoxide, and therefore doesn't present the same medical risks as cigarettes. NICODERM(R) provides 24 hour rate-controlled delivery of nicotine following its application to intact skin. NICODERM(R) reduces the withdrawal symptoms associated with smoking cessation and thus increases the success rate of smoking cessation programs. NICODERM(R) is the only patch that has a rate controlling membrane, to give your body a steady supply of nicotine to help protect you against cravings. Following the first NICODERM(R) application, the plasma nicotine concentration rises rapidly, plateaus within 2 to 4 hours and then slowly declines until the system is removed; after which it declines more rapidly. Nicotine in the adhesive layer is absorbed into and through the skin, causing the initial rapid rise in plasma concentration. The nicotine from the reservoir is released slowly through the membrane with a constant release rate. The rate of release of nicotine from the NICODERM(R) 14 mg/24 hour patch is 1.0 mg/hr. Following the second daily NICODERM(R) system application, steady state plasma nicotine concentration is achieved and is on average 30% higher compared with single dose applications. The quit rate for NICODERM(R) 14 mg/day was 54%. The unique feature offers 24-hour protection, even against the early morning cravings many people find the most difficult. Combination Nicotine Replacement Therapy - Nicoderm(R) patch + as needed Nicorette(R) gum/lozenge/oral inhaler/ oral mist versus mono Nicotine Replacement Therapy is: - Clinically proven to increase your chances of quitting. - A clinically proven approach to increase your chances of quitting for good. -If you have a relapse or experience tough/intense cravings or failed with the patch alone, you can use the patch with as needed Nicorette(R) gum/lozenge/oral inhaler/oral mist at the same time to increase your chances of quit success. - Now you can have the combined support of NICODERM(R) patch and NICORETTE(R) as needed gum/lozenge, oral inhaler/ oral mist products together, for a successful quit. - Tackle cravings: NICODERM(R) (patch) for slow release constant support and NICORETTE(R) as needed (gum/lozenge, oral inhaler/ oral mist) for an extra quick fix/dose when you really need to fight back the cravings / when something triggers intense cravings. - Combination therapy is 30%/1.3x more effective than using one Nicotine Replacement Therapy product alone. - Use NICODERM® patch + NICORETTE® (gum/lozenge/inhaler/oral mist) together to increase your chance of quitting.

A use authorised in Canada is not an authorised health claim in the European Union. See the health claims register.

Warnings in Canada

No French warning text available in the imported data.

Warnings are available in English on the official record.

Source

Official Health Canada record, licence 02093138

Licensed Natural Health Products Database (LNHPD), Health Canada: licensed products, ingredients, doses, uses and risks, retrieved 27 October 2026.

Contains information licensed under the Open Government Licence – Canada (Health Canada, LNHPD)

Licence du gouvernement ouvert – Canada 2.0 (OGL-Canada 2.0)

The formula sold in Europe under the same name may differ. This information does not replace advice from a doctor or pharmacist.

List in the official revision dated 26 July 2024 (register: Licensed Natural Health Products Database (LNHPD), Health Canada: licensed products, ingredients, doses, uses and risks).

List recorded in 2024. Photograph the packaging to check whether it has changed. Photograph the packaging